Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 94


TRF2 inhibits a cell-extrinsic pathway through which natural killer cells eliminate cancer cells.

Biroccio A, Cherfils-Vicini J, Augereau A, Pinte S, Bauwens S, Ye J, Simonet T, Horard B, Jamet K, Cervera L, Mendez-Bermudez A, Poncet D, Grataroli R, de Rodenbeeke CT, Salvati E, Rizzo A, Zizza P, Ricoul M, Cognet C, Kuilman T, Duret H, Lépinasse F, Marvel J, Verhoeyen E, Cosset FL, Peeper D, Smyth MJ, Londoño-Vallejo A, Sabatier L, Picco V, Pages G, Scoazec JY, Stoppacciaro A, Leonetti C, Vivier E, Gilson E.

Nat Cell Biol. 2013 Jul;15(7):818-28. doi: 10.1038/ncb2774. Epub 2013 Jun 23.


Sp1 upregulates expression of TRF2 and TRF2 inhibition reduces tumorigenesis in human colorectal carcinoma cells.

Dong W, Shen R, Wang Q, Gao Y, Qi X, Jiang H, Yao J, Lin X, Wu Y, Wang L.

Cancer Biol Ther. 2009 Nov;8(22):2166-74. Epub 2009 Nov 21.


Tumor microenvironmental conversion of natural killer cells into myeloid-derived suppressor cells.

Park YJ, Song B, Kim YS, Kim EK, Lee JM, Lee GE, Kim JO, Kim YJ, Chang WS, Kang CY.

Cancer Res. 2013 Sep 15;73(18):5669-81. doi: 10.1158/0008-5472.CAN-13-0545. Epub 2013 Jul 18.


Coordinate regulation between expression levels of telomere-binding proteins and telomere length in breast carcinomas.

Butler KS, Hines WC, Heaphy CM, Griffith JK.

Cancer Med. 2012 Oct;1(2):165-75. doi: 10.1002/cam4.14. Epub 2012 Jul 24.


Molecular characterization of collaborator of ARF (CARF) as a DNA damage response and cell cycle checkpoint regulatory protein.

Singh R, Kalra RS, Hasan K, Kaul Z, Cheung CT, Huschtscha L, Reddel RR, Kaul SC, Wadhwa R.

Exp Cell Res. 2014 Apr 1;322(2):324-34. doi: 10.1016/j.yexcr.2014.01.022. Epub 2014 Jan 28.


Elevated levels of TRF2 induce telomeric ultrafine anaphase bridges and rapid telomere deletions.

Nera B, Huang HS, Lai T, Xu L.

Nat Commun. 2015 Dec 7;6:10132. doi: 10.1038/ncomms10132.


TRF2 inhibition triggers apoptosis and reduces tumourigenicity of human melanoma cells.

Biroccio A, Rizzo A, Elli R, Koering CE, Belleville A, Benassi B, Leonetti C, Stevens MF, D'Incalci M, Zupi G, Gilson E.

Eur J Cancer. 2006 Aug;42(12):1881-8. Epub 2006 Jun 5.


TIN2 binds TRF1 and TRF2 simultaneously and stabilizes the TRF2 complex on telomeres.

Ye JZ, Donigian JR, van Overbeek M, Loayza D, Luo Y, Krutchinsky AN, Chait BT, de Lange T.

J Biol Chem. 2004 Nov 5;279(45):47264-71. Epub 2004 Aug 16.


Tumor sialylation impedes T cell mediated anti-tumor responses while promoting tumor associated-regulatory T cells.

Perdicchio M, Cornelissen LA, Streng-Ouwehand I, Engels S, Verstege MI, Boon L, Geerts D, van Kooyk Y, Unger WW.

Oncotarget. 2016 Feb 23;7(8):8771-82. doi: 10.18632/oncotarget.6822.


Molecular targeting of TRF2 suppresses the growth and tumorigenesis of glioblastoma stem cells.

Bai Y, Lathia JD, Zhang P, Flavahan W, Rich JN, Mattson MP.

Glia. 2014 Oct;62(10):1687-98. doi: 10.1002/glia.22708. Epub 2014 Jun 7.


Susceptibility to natural killer cell-mediated lysis of colon cancer cells is enhanced by treatment with epidermal growth factor receptor inhibitors through UL16-binding protein-1 induction.

Bae JH, Kim SJ, Kim MJ, Oh SO, Chung JS, Kim SH, Kang CD.

Cancer Sci. 2012 Jan;103(1):7-16. doi: 10.1111/j.1349-7006.2011.02109.x. Epub 2011 Nov 15.


TRF2 promotes multidrug resistance in gastric cancer cells.

Ning H, Li T, Zhao L, Li T, Li J, Liu J, Liu Z, Fan D.

Cancer Biol Ther. 2006 Aug;5(8):950-6. Epub 2006 Aug 2.


Direct incorporation of the NKT-cell activator α-galactosylceramide into a recombinant Listeria monocytogenes improves breast cancer vaccine efficacy.

Singh M, Quispe-Tintaya W, Chandra D, Jahangir A, Venkataswamy MM, Ng TW, Sharma-Kharkwal S, Carreño LJ, Porcelli SA, Gravekamp C.

Br J Cancer. 2014 Nov 11;111(10):1945-54. doi: 10.1038/bjc.2014.486. Epub 2014 Oct 14.


Accumulation and altered localization of telomere-associated protein TRF2 in immortally transformed and tumor-derived human breast cells.

Nijjar T, Bassett E, Garbe J, Takenaka Y, Stampfer MR, Gilley D, Yaswen P.

Oncogene. 2005 May 5;24(20):3369-76.


Elevated TRF2 in advanced breast cancers with short telomeres.

Diehl MC, Idowu MO, Kimmelshue KN, York TP, Jackson-Cook CK, Turner KC, Holt SE, Elmore LW.

Breast Cancer Res Treat. 2011 Jun;127(3):623-30. doi: 10.1007/s10549-010-0988-7. Epub 2010 Jul 13.


POT1 and TRF2 cooperate to maintain telomeric integrity.

Yang Q, Zheng YL, Harris CC.

Mol Cell Biol. 2005 Feb;25(3):1070-80.


Over-expression of telomere binding factors (TRF1 & TRF2) in renal cell carcinoma and their inhibition by using SiRNA induce apoptosis, reduce cell proliferation and migration invitro.

Pal D, Sharma U, Singh SK, Kakkar N, Prasad R.

PLoS One. 2015 Mar 2;10(3):e0115651. doi: 10.1371/journal.pone.0115651. eCollection 2015.


The histone deacetylase inhibitor trichostatin a promotes apoptosis and antitumor immunity in glioblastoma cells.

Höring E, Podlech O, Silkenstedt B, Rota IA, Adamopoulou E, Naumann U.

Anticancer Res. 2013 Apr;33(4):1351-60.


Supplemental Content

Support Center